Table 1.

11-1F4 binding to plate immobilized phage and Len peptides and the inhibitory effects of these molecules on antibody binding to immobilized Len(1–22).

			Immobilized Polypeptide		Solution-Phase Competition
Polypeptide	Phage Peptide Groupa	Sequenceb	EC50c(nM)	NaSCN assay IC50d(µM)	IC50e(µM)
Len VL	n.a.f	DIVMTQSPDSLAVSLGERATIN…	0.18 ± 0.03	3.9	≫30
a12	I	K-HYAAFPENLLI	0.54 ± 0.3	3.7 (3.9)	1.5 ± 0.1
g4	I	-VQYSSSPEALRV	14 ± 6.0	3.7 (4.0)	3.2 ± 0.0
f11	II	-IVYTPHPEYLW-P	32 ± 0.1	3.3 (3.9)	6.7 ± 0.1
b2	II	TYQYSPYPEPVM	44 ± 0.1	0.5 (0.5)	4.6 ± 0.1
a7	II	KPT-YSPYPFSM--P	18 ± 0.1	2.3 (0.5)	1.7 ± 0.1
Len(1–22)	n.a.	DIVMTQSPDSLAVSLGERATIN	0.24 ± 0.1	1.37	0.07 ± 0.01
Len(1–15)	n.a.	DIVMTQSPDSLAVSL	0.39 ± 0.05	n.d.g	0.27 ± 0.01
Len(1–13)	n.a.	DIVMTQSPDSLAV	16 ± 0.1	n.d.	33 ± 0.07

^aPhage peptides were grouped based on the presence of highly conserved proline residues, as shown in Fig. 1.

^bPeptide sequences were aligned by CLUSTALW (29); hydrophobic and/or aromatic residues are bolded and proline is underlined.

^cEach EC₅₀ value was determined from the midpoint of 11-1F4 titration curves, as shown in Figure 4a and Figure 7a.

^dEach IC₅₀ value was determined from the midpoint of NaSCN titration curves (see Figure 3a and b). IC₅₀ values with or without brackets were determined for 11-1F4 binding to phage peptides alone or expressed on phage particles, respectively.

^eEach IC₅₀ value was determined from the midpoint of peptide competition curves shown in Figure 4b and Figure 7b.

^fn.a., not applicable.

^gn.d., not determined.